Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study

Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (U100; Humalog(®); Ly-Lis). This study aimed to show similar efficacy, safety, and immunogenicity of SAR-Lis versus Ly-Lis in adult patients with type 2 diabetes mellitus (T2DM) treated with multiple daily injections, whil...

Descripción completa

Detalles Bibliográficos
Autores principales: Derwahl, Karl-Michael, Bailey, Timothy S., Wernicke-Panten, Karin, Ping, Lin, Pierre, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770084/
https://www.ncbi.nlm.nih.gov/pubmed/29232162
http://dx.doi.org/10.1089/dia.2017.0281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770084/
https://www.ncbi.nlm.nih.gov/pubmed/29232162
http://dx.doi.org/10.1089/dia.2017.0281

Ejemplares similares